Home > About us > 

Dr. Li Jinliang was Selected into National “Ten-thousand Talents Program”

Source:DESANO      Date:2019-03-21 16:18:22

A few days ago, the general office of the organization department of the CPC central committee issued the notice on the issuance of the list of the fourth group of national " Ten-thousand Talents Program " candidates, among which 645 people are leading talents in scientific and technological innovation, 397 people are leading talents in scientific and technological entrepreneurship, 103 people are reputable teachers. 210 people are outstanding young talents (major in natural science). Dr. Li Jinliang, chairman of Shanghai Desano Chemical Pharmaceutical Co., Ltd., was selected as the leading talent of science & technology entrepreneurship.

Introduction of National“Ten-thousand Talents Program”

The national "Ten-thousand Talents Program", formally initiated in September 2012, is called the "National Special Support Plan for High-Level Talents", referred to as the "National Special Support Plan", also known as the "Ten-thousand Talents Program". National "Ten-thousand Talents Program" is a high-level talents support plan covering wild areas, involving many departments, with long period of implementation. It is jointly launched by 11 departments including the Organization Department of the Central Committee of the CPC and MOLSS to special support outstanding, leading and top-notch young talents in the fields of natural science, engineering technology, philosophy and social science nationwide, so as to speed up the training of a group of high-level innovative and entrepreneurial talents who will provide strong support for building an innovation-oriented country.

The "Ten-thousand Talents Program" focuses on supporting talents of three levels and seven categories according to the idea of high-end guidance and echelon allocation. The first level is the "Outstanding talents" program, which aims to support 100 talents who are at the forefront of world science and technology, have made important discoveries in scientific research, and have the potential to grow into world-class scientists. The second level is "Leading talents". It is planned to support 8,000 innovation and entrepreneurship talents that are urgently needed by nation in science and technology development and industrial development, including leading talents in science and technology innovation, leading talents in science and technology entrepreneurship, leading talents in philosophy and social sciences, famous teachers and leading talents in engineering. The third level is the "Top young talents" program, which aims to support 2,000 young talents under the age of 35 with outstanding scientific research and technological innovation potential and important innovation prospects in scientific research.

Introduction of Dr. Li Jinliang

Dr. Li jinliang is currently the president of Shanghai Desano Chemical Pharmaceutical Co., Ltd., and the director of the National Anti-HIV Drug Engineering Technology Research Center. He has been awarded "Shanghai youth outstanding contribution award for science and technology", "Shanghai leading talent", "Shanghai outstanding technical leader", "Shanghai model worker collective leader", "Shanghai science and technology entrepreneur innovation award", "Outstanding leader award", "Shanghai social undertakings elite award" etc.

He led the team to carry out scientific and technological innovation of anti-HIV drugs, and presided over the completion of 14 national projects such as the creation of major new drugs, 4 national key new products and 3 key new products in Shanghai. 149 invention patents have been applied and 45 patents have been authorized. Among them, new drug Nevirapine and Lamivudine were awarded the third prize of Shanghai science and technology progress award. The commercialization of many new products has provided strong technical support and leading role for the development of Desano. It has promoted the popularization of antiviral treatment in China and the world, benefiting more than 500,000 HIV patients in China and more than 6 million HIV patients in the world, saving more than 10 billion Chinese yuan in treatment funds for the country and providing a strong drug guarantee for HIV prevention and treatment in China and the whole world.

In the future, "Produce the best and cheapest anti-HIV drugs to enable more HIV patients to live like normal people" has become the objective of Desano's continuous struggle. Under the leadership of Dr. Li jinliang, Desano will continue to maintain its high-tech characteristics, continue to increase scientific and technological innovation, as well as continue to enhance industry-university-research cooperation to benefit more HIV patients.